BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8956783)

  • 1. In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022.
    McLeod HL; Brunton VG; Eckardt N; Lear MJ; Robins DJ; Workman P; Graham MA
    Br J Cancer; 1996 Dec; 74(11):1714-8. PubMed ID: 8956783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice.
    Yoneda T; Lyall RM; Alsina MM; Persons PE; Spada AP; Levitzki A; Zilberstein A; Mundy GR
    Cancer Res; 1991 Aug; 51(16):4430-5. PubMed ID: 1651159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase inhibitors as antiproliferative agents against an estrogen-dependent breast cancer cell line in vitro.
    Twaddle GM; Turbov J; Liu N; Murthy S
    J Surg Oncol; 1999 Feb; 70(2):83-90. PubMed ID: 10084649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiproliferative effects of tyrosine kinase inhibitors (tyrphostins) on human bladder and renal carcinoma cells.
    Sion-Vardy N; Vardy D; Rodeck U; Kari C; Levin RM; Malkowicz SB
    J Surg Res; 1995 Dec; 59(6):675-80. PubMed ID: 8538164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein binding modulates inhibition of the epidermal growth factor receptor kinase and DNA synthesis by tyrphostins.
    Hoffman R; Dennis IF; Donaldson J
    Cancer Chemother Pharmacol; 1995; 36(4):316-24. PubMed ID: 7628051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth inhibition of gastric cancer cell lines by the tyrphostin RG13022 and its effects on intracellular signalling.
    McLaughlin M; Brunton V; Morrison V; Rae A; Cooke T; Bartlett J
    Int J Oncol; 1996 Mar; 8(3):589-96. PubMed ID: 21544401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5.
    Modjtahedi H; Affleck K; Stubberfield C; Dean C
    Int J Oncol; 1998 Aug; 13(2):335-42. PubMed ID: 9664130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitor as a novel signal transduction and antiproliferative agent: prostate cancer.
    Kondapaka BS; Reddy KB
    Mol Cell Endocrinol; 1996 Mar; 117(1):53-8. PubMed ID: 8734473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tyrphostin on cell growth and tyrosine kinase activity of epidermal growth factor receptor in human gliomas.
    Miyaji K; Tani E; Shindo H; Nakano A; Tokunaga T
    J Neurosurg; 1994 Sep; 81(3):411-9. PubMed ID: 8057149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor.
    Reddy KB; Mangold GL; Tandon AK; Yoneda T; Mundy GR; Zilberstein A; Osborne CK
    Cancer Res; 1992 Jul; 52(13):3636-41. PubMed ID: 1617636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid uptake of tyrphostin into A431 human epidermoid cells is followed by delayed inhibition of epidermal growth factor (EGF)-stimulated EGF receptor tyrosine kinase activity.
    Faaland CA; Mermelstein FH; Hayashi J; Laskin JD
    Mol Cell Biol; 1991 May; 11(5):2697-703. PubMed ID: 1850101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in EGF-dependent proliferative and phosphorylation events in squamous cell carcinoma cell lines by a tyrosine kinase inhibitor.
    Brunton VG; Carlin S; Workman P
    Anticancer Drug Des; 1994 Aug; 9(4):311-29. PubMed ID: 7916899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of tyrphostin combined with a substance P related antagonist on small cell lung cancer cell growth in vitro.
    Seckl MJ; Rozengurt E
    Eur J Cancer; 1996 Feb; 32A(2):342-5. PubMed ID: 8664052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
    Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
    J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
    Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Regenass U; Lydon NB
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2558-62. PubMed ID: 7708684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
    Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
    J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia.
    Kaur G; Gazit A; Levitzki A; Stowe E; Cooney DA; Sausville EA
    Anticancer Drugs; 1994 Apr; 5(2):213-22. PubMed ID: 8049505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of pancreatic cancer cell growth in vitro by the tyrphostin group of tyrosine kinase inhibitors.
    Gillespie J; Dye JF; Schachter M; Guillou PJ
    Br J Cancer; 1993 Dec; 68(6):1122-6. PubMed ID: 8260363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.
    Johns TG; Luwor RB; Murone C; Walker F; Weinstock J; Vitali AA; Perera RM; Jungbluth AA; Stockert E; Old LJ; Nice EC; Burgess AW; Scott AM
    Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15871-6. PubMed ID: 14676326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.